New painkillers from snail venom
A compound contained in the venom of the predatory snail Conus regius of the snail familyóin the sea – coneów, has a strong anti-bólowe. It is the compound RgIA and its existence was already known to scientists, but now, thanks to researchers at the University of Utah, there is a chance for new drugs against bólowe.
Conus regius uses venom to incapacitate and kill its victims. This venom contains the compound RgIA, whichóry has strong anti-bólowe. The substance interacts with completely different receptors than the commonly used opioid drugs against bólowe. This is important because the new antibólne roots based on snail venom may provide an alternative to drugsóin opioid.
In the United States, the opening of the mówi is about the opioid drug addiction crisisóin counterbólowe. These agents are addictive and cause about 90 deathsóin a day in the US as a result of an overdose of. New drugs against ból based on snail venom could stem the crisis. This is also an opportunity for waspsób suffering from bóle chronic.
– Nature has created many molecules. Someóre of them are very sophisticated and may have unexpected applications. We have long been interested in the use of venomów to learn and understand ródifferent signaling pathways in our nervous system – said Professor Baldomero Olivera of the University of Utah.
It was this snail, which is commonly found in the Caribbean Sea, that showed scientists the signal pathway used to block bólu, whichóry is different from that used by opioid drugs.
Researchers were already aware of the RgIA compound, but it had not been thoroughly studied. It ended up in experiments with rats, where some surprising facts were observed. The compound has anti-ból longer than RgIA persists in the body. The compound is excreted after about four hours, but the effects can last up to 72 hours. This means that RgIA can reconstruct someóre elements of the nervous system.
Researchers at the University of Utah based on previous research and with the help of chemical engineering developed the compound RgIA4, który binds to the human receptor. Preparations are currently underway to testów.
The results of the work of American scientists were published on „Proceedings of the National Academy of Science”.